Biomarin Pharmaceutical (BMRN) Profit After Tax (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Profit After Tax came in at $105.5 million in Q1 2026, down 43.17% YoY from $185.7 million in Q1 2025, and up 326.58% on a QoQ basis from -$46.6 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Profit After Tax (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Profit After Tax data on file, last reported at $105.5 million in Q1 2026.
- Quarterly Profit After Tax fell 43.17% year-over-year to $105.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.0 million (down 61.29% YoY) and the FY2025 annual result came in at $348.9 million, down 18.26% from the prior year.
- Profit After Tax improved to $105.5 million in Q1 2026, from -$46.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $185.7 million in Q1 2025 to a low of -$46.6 million in Q4 2025.
- A 5-year average of $66.9 million and a median of $48.1 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 8282.73% — and 2025, when it slumped 137.28%.
- Tracing BMRN's Profit After Tax over 5 years: stood at -$249000.0 in 2022, then soared by 8282.73% to $20.4 million in 2023, then jumped by 513.22% to $124.9 million in 2024, then tumbled by 137.28% to -$46.6 million in 2025, then soared by 326.58% to $105.5 million in 2026.
- The last three Profit After Tax figures came in at $105.5 million (Q1 2026), -$46.6 million (Q4 2025), and -$30.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 44.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.76 Mn |
| Mar 31, 2026 | 105.53 Mn |
| Dec 31, 2025 | -46.57 Mn |
| Sep 30, 2025 | -30.74 Mn |
| Jun 30, 2025 | 176.82 Mn |
| Mar 31, 2025 | 185.69 Mn |
| Dec 31, 2024 | 124.94 Mn |
| Sep 30, 2024 | 83.93 Mn |
| Jun 30, 2024 | 135.02 Mn |
| Mar 31, 2024 | 88.66 Mn |
| Dec 31, 2023 | 20.38 Mn |
| Sep 30, 2023 | 40.38 Mn |
| Jun 30, 2023 | 48.15 Mn |
| Mar 31, 2023 | 44.00 Mn |
| Dec 31, 2022 | -249,000.00 |
| Sep 30, 2022 | -6.65 Mn |
| Jun 30, 2022 | 47.01 Mn |
| Mar 31, 2022 | 120.80 Mn |
| Dec 31, 2021 | -57.90 Mn |
| Sep 30, 2021 | -36.49 Mn |